Quick Answer
IO Biotech, Inc. reported Operating Income of -$95.18 million for fiscal year 2024.
IO Biotech, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$95.18M | -4.1% |
| 2023 | -$91.44M | -28.0% |
| 2022 | -$71.42M | -73.2% |
| 2021 | -$41.23M | -306.4% |
| 2020 | -$10.14M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$19.36M | +27.0% | +16.5% |
| June 30, 2025 | -$23.17M | -7.6% | -2.6% |
| March 31, 2025 | -$22.58M | -11.8% | +14.8% |
| September 30, 2024 | -$26.50M | -12.9% | -23.1% |
| June 30, 2024 | -$21.53M | +1.5% | -6.6% |
| March 31, 2024 | -$20.20M | -12.7% | +14.0% |
| September 30, 2023 | -$23.48M | -48.0% | -7.5% |
| June 30, 2023 | -$21.85M | -20.3% | -21.9% |
- IO Biotech, Inc. showed a decrease of -4.1% in Operating Income compared to the prior fiscal year.
- Over the 2020–2024 period, IO Biotech, Inc.’s operating income has declined by 838.2% (from -$10.14 million to -$95.18 million).
- The most recent figure is from IO Biotech, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: